Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 14/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917812 | 0.91 | MAPT (0.34) | CYP2D6CYP3A4NPC1LTA4HSMN1; SMN2 | |
| SCHEMBL4919465 | 0.82 | — | — | |
| SCHEMBL4924798 | 0.74 | LTA4H (0.35) | CYP2D6CYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1494205 | 0.74 | CYP2D6 (0.42) | CYP2D6CYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4765692 | 0.72 | CYP1A2 (0.51) | CYP2D6CYP19A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL277285 | 0.71 | — | — | |
| SCHEMBL10388858 | 0.70 | CYP2D6 (0.49) | CYP2D6CYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1494545 | 0.69 | LTA4H (0.40) | CYP2D6CYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1494281 | 0.68 | LMNA (0.40) | CYP2D6CYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL1494604 | 0.68 | LMNA (0.40) | CYP2D6CYP3A4CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | CYP2D6 113/4885CYP3A4 325/4885CYP19A1 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.